Hirofumi Mukai Selected Research

Hirofumi Mukai Research Topics

Disease

101	Breast Neoplasms (Breast Cancer) 12/2023 - 03/2002
48	Neoplasms (Cancer) 03/2024 - 03/2002
19	Neutropenia 09/2021 - 03/2007
7	Neoplasm Metastasis (Metastasis) 10/2022 - 10/2012
6	Stomatitis 04/2021 - 11/2014
5	Fatigue 10/2022 - 04/2010
5	Diarrhea 09/2021 - 07/2008
5	Disease Progression 09/2016 - 02/2009
4	Leukopenia 09/2021 - 06/2007
4	Febrile Neutropenia 04/2021 - 02/2011
4	Prostatic Neoplasms (Prostate Cancer) 12/2017 - 04/2014
4	Exanthema (Rash) 10/2016 - 07/2008
4	Carcinoma (Carcinomatosis) 07/2013 - 02/2003
3	Peripheral Nervous System Diseases (PNS Diseases) 12/2022 - 10/2020
2	Pathologic Complete Response 11/2023 - 08/2014
2	Mucositis 04/2021 - 01/2020
2	Lymphatic Metastasis 01/2021 - 08/2010
2	Alopecia (Baldness) 11/2020 - 10/2016
2	Thrombocytopenia (Thrombopenia) 01/2019 - 10/2015
2	Vomiting 03/2017 - 08/2010
2	Nausea 03/2017 - 08/2010
2	Dyspnea (Shortness of Breath) 11/2014 - 10/2012
1	Cerebral Infarction 03/2024
1	Hemorrhage 03/2024
1	Venous Thromboembolism 03/2024
1	Transient Ischemic Attack 03/2024
1	Triple Negative Breast Neoplasms 11/2023
1	Carcinoma in Situ 11/2023
1	Second Primary Neoplasms (Neoplasms, Second) 01/2023
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022
1	Cognitive Dysfunction 08/2021
1	Vascular Remodeling 07/2021

Drug/Important Bio-Agent (IBA)

23	Trastuzumab (Herceptin)FDA Link 12/2022 - 03/2002
20	Hormones (Hormone)IBA 01/2023 - 06/2010
18	ErbB Receptors (EGF Receptor)IBA 10/2022 - 12/2012
15	Estrogen ReceptorsIBA 12/2023 - 08/2010
15	taxaneIBA 12/2022 - 08/2010
9	palbociclibIBA 08/2022 - 06/2016
9	human ERBB2 proteinIBA 03/2022 - 10/2009
7	eribulin FDA Link 07/2021 - 10/2012
7	exemestane (Aromasin)FDA Link 04/2021 - 05/2013
7	Everolimus FDA Link 04/2021 - 05/2013
7	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 08/2010
7	Docetaxel (Taxotere)FDA Link 03/2017 - 02/2003
6	Aromatase InhibitorsIBA 01/2023 - 06/2010
6	Letrozole (Femara)FDA LinkGeneric 08/2022 - 11/2014
5	Lapatinib (GW572016)FDA Link 09/2023 - 01/2007
5	Anastrozole (Arimidex)FDA LinkGeneric 01/2023 - 06/2010
5	AnthracyclinesIBA 10/2021 - 01/2013
5	Biomarkers (Surrogate Marker)IBA 10/2021 - 04/2010
5	Taxoids (Taxanes)IBA 01/2016 - 08/2010
4	130-nm albumin-bound paclitaxelIBA 12/2022 - 02/2021
4	Epidermal Growth Factor (EGF)IBA 10/2021 - 01/2013
3	Cyclin-Dependent Kinase 4IBA 08/2022 - 06/2016
3	Fulvestrant (Faslodex)FDA Link 08/2022 - 03/2019
3	Progesterone Receptors (Progesterone Receptor)IBA 10/2021 - 01/2016
3	Dexamethasone (Maxidex)FDA LinkGeneric 04/2021 - 02/2003
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 07/2020 - 06/2007
3	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2020 - 03/2007
3	Tamoxifen FDA LinkGeneric 11/2014 - 06/2010
3	Cisplatin (Platino)FDA LinkGeneric 12/2013 - 02/2003
3	Phosphotransferases (Kinase)IBA 02/2009 - 01/2007
2	LigandsIBA 11/2023 - 05/2011
2	abemaciclibIBA 08/2022 - 09/2021
2	Anti-Bacterial Agents (Antibiotics)IBA 04/2021 - 07/2016
2	Gemcitabine FDA Link 01/2020 - 12/2013
2	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 08/2010
2	Carboplatin (JM8)FDA LinkGeneric 01/2020 - 01/2019
2	NK105IBA 01/2019 - 12/2016
2	Androgen Receptor AntagonistsIBA 12/2017 - 12/2017
2	darolutamideIBA 12/2017 - 12/2017
2	Fluorouracil (Carac)FDA LinkGeneric 01/2016 - 08/2010
2	cabazitaxel FDA Link 10/2015 - 04/2014
2	EnzymesIBA 11/2014 - 07/2008
2	titanium silicide (TS-1)IBA 07/2014 - 08/2010
2	Tyrosine (L-Tyrosine)FDA Link 02/2009 - 01/2007
1	fibrin fragment D (D-dimer)IBA 03/2024
1	pembrolizumabIBA 11/2023
1	Estradiol (Delestrogen)FDA LinkGeneric 09/2023
1	Fatty Acids (Saturated Fatty Acids)IBA 09/2023
1	Glucose (Dextrose)FDA LinkGeneric 09/2023
1	ElementsIBA 08/2022
1	vinyltriethoxysilane (VTES)IBA 01/2022
1	pyrimidineIBA 10/2021
1	ParaffinIBA 10/2021
1	TubulinIBA 10/2021
1	Formaldehyde (Formol)FDA Link 10/2021
1	pegfilgrastim (Neulasta)FDA Link 04/2021

Therapy/Procedure

46	Therapeutics 12/2023 - 03/2002
40	Drug Therapy (Chemotherapy) 11/2023 - 06/2003
9	Neoadjuvant Therapy 11/2023 - 03/2007
6	Drug Tapering 10/2022 - 10/2015
6	Radiotherapy 04/2021 - 01/2013
4	Adjuvant Chemotherapy 03/2022 - 12/2013
4	Castration 12/2017 - 04/2014
3	Combination Drug Therapy (Combination Chemotherapy) 01/2020 - 02/2003
3	Complementary Therapies (Alternative Medicine) 01/2018 - 12/2006
2	Duration of Therapy 01/2019 - 06/2018
1	Ambulatory Care (Outpatient Care) 11/2022
1	Time-to-Treatment 10/2022